Predictors of Adherence to Orencia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01136707

Enrollment

422

Registered

2010-06-03

Start date

2009-12-31

Completion date

2010-07-31

Last updated

2016-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The purpose of this study is to examine the relationship between loading dose and adherence to Orencia.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients will be identified based on the presence of first infusion claim during study period for Orencia * At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date * Patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below * Patients with a minimum of 3 infusion claims for Orencia * Only those patients will be included whose first 3 infusion claims occur within 84 days

Exclusion criteria

* Patients less than 18 years of age at index date. * One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period * Patients who switch between biologics within their first three infusion claims * Restarts, defined as those patients who go back on Orencia after a gap of 42 days * Patients who are on other biologics at the same time as Orencia

Design outcomes

Primary

Measure	Time frame
Total number of days on Orencia therapy	6 months

Secondary

Measure	Time frame
Rheumatoid arthritis-related and total healthcare costs	6 months

Outcome results